138 related articles for article (PubMed ID: 29328370)
1. Ammonium tetrathiomolybdate enhances the antitumor effects of cetuximab via the suppression of osteoclastogenesis in head and neck squamous carcinoma.
Morisawa A; Okui T; Shimo T; Ibaragi S; Okusha Y; Ono M; Nguyen TTH; Hassan NMM; Sasaki A
Int J Oncol; 2018 Mar; 52(3):989-999. PubMed ID: 29328370
[TBL] [Abstract][Full Text] [Related]
2. Ammonium tetrathiomolybdate enhances the antitumor effect of cisplatin via the suppression of ATPase copper transporting beta in head and neck squamous cell carcinoma.
Ryumon S; Okui T; Kunisada Y; Kishimoto K; Shimo T; Hasegawa K; Ibaragi S; Akiyama K; Thu Ha NT; Monsur Hassan NM; Sasaki A
Oncol Rep; 2019 Dec; 42(6):2611-2621. PubMed ID: 31638244
[TBL] [Abstract][Full Text] [Related]
3. Cetuximab sensitivity of head and neck squamous cell carcinoma xenografts is associated with treatment-induced reduction in EGFR, pEGFR, and pSrc.
Jedlinski A; Garvin S; Johansson AC; Edqvist PH; Ponten F; Roberg K
J Oral Pathol Med; 2017 Oct; 46(9):717-724. PubMed ID: 28036101
[TBL] [Abstract][Full Text] [Related]
4. Semaphorin 4D promotes bone invasion in head and neck squamous cell carcinoma.
Takada H; Ibaragi S; Eguchi T; Okui T; Obata K; Masui M; Morisawa A; Takabatake K; Kawai H; Yoshioka N; Hassan NMM; Shimo T; Hu GF; Nagatsuka H; Sasaki A
Int J Oncol; 2017 Aug; 51(2):625-632. PubMed ID: 28656278
[TBL] [Abstract][Full Text] [Related]
5. The inhibition of RANKL/RANK signaling by osteoprotegerin suppresses bone invasion by oral squamous cell carcinoma cells.
Shin M; Matsuo K; Tada T; Fukushima H; Furuta H; Ozeki S; Kadowaki T; Yamamoto K; Okamoto M; Jimi E
Carcinogenesis; 2011 Nov; 32(11):1634-40. PubMed ID: 21890459
[TBL] [Abstract][Full Text] [Related]
6. HER3 Targeting Sensitizes HNSCC to Cetuximab by Reducing HER3 Activity and HER2/HER3 Dimerization: Evidence from Cell Line and Patient-Derived Xenograft Models.
Wang D; Qian G; Zhang H; Magliocca KR; Nannapaneni S; Amin AR; Rossi M; Patel M; El-Deiry M; Wadsworth JT; Chen Z; Khuri FR; Shin DM; Saba NF; Chen ZG
Clin Cancer Res; 2017 Feb; 23(3):677-686. PubMed ID: 27358485
[TBL] [Abstract][Full Text] [Related]
7. Combination of phosphotidylinositol-3-kinase targeting with cetuximab and irradiation: A preclinical study on an orthotopic xenograft model of head and neck cancer.
Bozec A; Ebran N; Radosevic-Robin N; Chamorey E; Yahia HB; Marcie S; Gautier M; Penault-Llorca F; Milano G
Head Neck; 2017 Jan; 39(1):151-159. PubMed ID: 27507562
[TBL] [Abstract][Full Text] [Related]
8. High-mobility group box 1 induces bone destruction associated with advanced oral squamous cancer via RAGE and TLR4.
Sakamoto Y; Okui T; Yoneda T; Ryumon S; Nakamura T; Kawai H; Kunisada Y; Ibaragi S; Masui M; Ono K; Obata K; Shimo T; Sasaki A
Biochem Biophys Res Commun; 2020 Oct; 531(3):422-430. PubMed ID: 32800556
[TBL] [Abstract][Full Text] [Related]
9. Upregulation of secreted phosphoprotein 1 affects malignant progression, prognosis, and resistance to cetuximab via the KRAS/MEK pathway in head and neck cancer.
Liu K; Hu H; Jiang H; Liu C; Zhang H; Gong S; Wei D; Yu Z
Mol Carcinog; 2020 Oct; 59(10):1147-1158. PubMed ID: 32805066
[TBL] [Abstract][Full Text] [Related]
10. ASCT2 (SLC1A5)-dependent glutamine uptake is involved in the progression of head and neck squamous cell carcinoma.
Zhang Z; Liu R; Shuai Y; Huang Y; Jin R; Wang X; Luo J
Br J Cancer; 2020 Jan; 122(1):82-93. PubMed ID: 31819178
[TBL] [Abstract][Full Text] [Related]
11. The role of copper suppression as an antiangiogenic strategy in head and neck squamous cell carcinoma.
Cox C; Teknos TN; Barrios M; Brewer GJ; Dick RD; Merajver SD
Laryngoscope; 2001 Apr; 111(4 Pt 1):696-701. PubMed ID: 11359142
[TBL] [Abstract][Full Text] [Related]
12. Antitumor effect of temsirolimus against oral squamous cell carcinoma associated with bone destruction.
Okui T; Shimo T; Fukazawa T; Kurio N; Hassan NM; Honami T; Takaoka M; Naomoto Y; Sasaki A
Mol Cancer Ther; 2010 Nov; 9(11):2960-9. PubMed ID: 20858724
[TBL] [Abstract][Full Text] [Related]
13. EPR Oximetry of Cetuximab-Treated Head-and-Neck Tumours in a Mouse Model.
Gustafsson H; Kale A; Dasu A; Lund A; Edqvist PH; Roberg K
Cell Biochem Biophys; 2017 Dec; 75(3-4):299-309. PubMed ID: 28756482
[TBL] [Abstract][Full Text] [Related]
14. Lysyl oxidase like-4 monoclonal antibody demonstrates therapeutic effect against head and neck squamous cell carcinoma cells and xenografts.
Görögh T; Quabius ES; Heidebrecht H; Nagy A; Muffels T; Haag J; Ambrosch P; Hoffmann M
Int J Cancer; 2016 May; 138(10):2529-38. PubMed ID: 26756583
[TBL] [Abstract][Full Text] [Related]
15. Combination tetrathiomolybdate and radiation therapy in a mouse model of head and neck squamous cell carcinoma.
Khan MK; Mamou F; Schipper MJ; May KS; Kwitny A; Warnat A; Bolton B; Nair BM; Kariapper MS; Miller M; Brewer G; Normolle D; Merajver SD; Teknos TN
Arch Otolaryngol Head Neck Surg; 2006 Mar; 132(3):333-8. PubMed ID: 16549755
[TBL] [Abstract][Full Text] [Related]
16. Elevated RET expression enhances EGFR activation and mediates EGFR inhibitor resistance in head and neck squamous cell carcinoma.
Lin C; Lu W; Ren Z; Tang Y; Zhang C; Yang R; Chen Y; Cao W; Wang L; Wang X; Ji T
Cancer Lett; 2016 Jul; 377(1):1-10. PubMed ID: 27090738
[TBL] [Abstract][Full Text] [Related]
17. Establishment of a xenograft model to explore the mechanism of bone destruction by human oral cancers and its application to analysis of role of RANKL.
Tohyama R; Kayamori K; Sato K; Hamagaki M; Sakamoto K; Yasuda H; Yamaguchi A
J Oral Pathol Med; 2016 May; 45(5):356-64. PubMed ID: 26859422
[TBL] [Abstract][Full Text] [Related]
18. LOX Fails to Substitute for RANKL in Osteoclastogenesis.
Tsukasaki M; Hamada K; Okamoto K; Nagashima K; Terashima A; Komatsu N; Win SJ; Okamura T; Nitta T; Yasuda H; Penninger JM; Takayanagi H
J Bone Miner Res; 2017 Mar; 32(3):434-439. PubMed ID: 27606829
[TBL] [Abstract][Full Text] [Related]
19. Acetyl-CoA carboxylase rewires cancer metabolism to allow cancer cells to survive inhibition of the Warburg effect by cetuximab.
Luo J; Hong Y; Lu Y; Qiu S; Chaganty BK; Zhang L; Wang X; Li Q; Fan Z
Cancer Lett; 2017 Jan; 384():39-49. PubMed ID: 27693630
[TBL] [Abstract][Full Text] [Related]
20. Hypoxia Mediates Differential Response to Anti-EGFR Therapy in HNSCC Cells.
Wiechec E; Hansson KT; Alexandersson L; Jönsson JI; Roberg K
Int J Mol Sci; 2017 Apr; 18(5):. PubMed ID: 28468237
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
